Abstract:Abstract Despite objective responses to poly(ADP-ribose) polymerase (PARP) inhibition and improvements in progression-free survival (PFS) compared to standard chemotherapy in patients with BRCA-associated triple-negative breast cancer (TNBC), benefits are transitory. Using high-dimensional single-cell profiling of human TNBC, here we demonstrate that macrophages are the predominant infiltrating immune cell type in breast cancer susceptibility (BRCA)-associated TNBC. Macrophages are an innate immune cell that play a critical role in host defense and maintaining tissue homeostasis, however their infiltration into tumors has been associated with disease progression and resistance to therapy. Tumor associated macrophages (TAMs) represent a significant proportion of solid tumors, including breast cancer. TAMs play a major role in tumorigenesis as they can enhance tumor cell growth, angiogenesis and metastasis. In addition, TAMs can inhibit anti-tumor responses of T cells. Our recent work has shown that removal or conversion of TAMs to an anti-tumor phenotype enhances chemo- and immuno-therapy establishing TAMs as targets for anti-cancer therapy. Through multi-omics profiling, we show that PARP inhibitors enhance both anti- and pro-tumor features of macrophages through glucose and lipid metabolic reprogramming, driven by the sterol regulatory element-binding protein 1 (SREBF1, SREBP1) pathway. Combining PARP inhibitor therapy with colony-stimulating factor 1 receptor (CSF1R)-blocking antibodies significantly enhanced innate and adaptive antitumor immunity and extended survival in mice with BRCA-deficient tumors in vivo, and this was mediated by CD8+ T cells. Collectively, our results uncover macrophage-mediated immune suppression as a liability of PARP inhibitor treatment and demonstrate that combined PARP inhibition and macrophage-targeting therapy induces a durable reprogramming of the tumor microenvironment (TME), thus constituting a promising therapeutic strategy for TNBC. Therefore, targeting TAMs offers great potential to enhance both chemo- and immuno-therapy. Deep analysis of TAMs in solid tumors has revealed the complexity of TAMs and revealed major gaps in our knowledge of the functional and phenotypic characterization of TAM subsets associated with cancer, before and after treatment. Here we will discuss the complexity of TAMs in solid tumors including characterizing TAM subsets, location, and crosstalk with neighboring cells, as well as novel TAM-modulating strategies and combinations that are likely to enhance current therapies and overcome chemo- and immuno-therapy resistance. Citation Format: Jennifer L. Guerriero. The complexities of tumor associated macrophages and the key to effective targeting for anti-cancer therapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr SY17-01.

Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?

Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion

Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

The matrix in cancer

Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments

The Role of Extracellular Matrix Proteins in Breast Cancer

Abstract SY37-03: Leveraging the complexities of tumor associated macrophages for effective anti-cancer therapy

Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment

The Role of Tumor-Associated Macrophages in Breast Cancer Progression

Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix

Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis

Advances in the Macrophages and Their Interaction with Tumor Cells

Macrophages as regulators of tumour immunity and immunotherapy

Tumor‐associated macrophages: A sentinel of innate immune system in tumor microenvironment gone haywire

Macrophages and cancer stem cells: a malevolent alliance

Abstract SY17-01: The complexities of tumor associated macrophages and the key to effective targeting for anti-cancer therapy

Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment

Integrated multiomics analysis unveils how macrophages drive immune suppression in breast tumors and affect clinical outcomes

Macrophages as tools and targets in cancer therapy